North East and North Cumbria
ICS Formulary
 
back
3 Respiratory system

*Important*

The NENC ICB Respiratory Network recommends that all inhalers should be prescribed by brand for patient safety, to ensure that the correct device is dispensed to support correct technique and avoid patient confusion and medication errors.

Choice of inhaler device should be based on patient ability to use. Devices should be chosen based on availability for the type of drug to be prescribed and the patient’s ability to use it.

Refer to local guidelines for information on preferred options.

Note: All new patients should be started on the updated formulary choices as per local/national guidelines.

When inhalers are removed from the formulary, existing, stable, patients should continue to receive the non-formulary device. Treatment should not be changed unless a full face to face review has been conducted.

03-01-02 Antimuscarinic bronchodilators

**The propellants used in pressurised Metered Dose Inhalers (pMDIs) have a high carbon footprint. Dry Powder Inhalers (DPIs) are now first choice for all of the different inhaler classes and should be used wherever this is clinically appropriate**


Tiotropium Respimat®
Formulary
  • 2.5mg Respimat® inhaler
    • Step 4 of the BTS/SIGN Asthma guidelines. Treatment should be stopped if not effective.


Link  MHRA Drug Safety Update (Feb 2015): Tiotropium delivered via Respimat compared with Handihaler: no significant difference in mortality in TIOSPIR trial

Green View adult BNF  View SPC online  View childrens BNF
Umeclidinium Incruse Ellipta®
Formulary

 

    • 55 microgram/dose (equivalent to umeclidinium bromide 65m microgram/dose) dry powder inhaler (DPI)



 


Green View adult BNF  View SPC online  View childrens BNF
Tiotropium Handihaler®
Formulary
  • 18 mcg inhalation powder capsule (Handihaler®) (DPI) 
    • For existing COPD patients only and those unable to use the other LAMA devices. Consideration should be given to switching at next review, providing adequate training / counselling is provided in device use.
Link  MHRA Drug Safety Update (Feb 2015): Tiotropium delivered via Respimat compared with Handihaler: no significant difference in mortality in TIOSPIR trial

Green View adult BNF  View SPC online  View childrens BNF
Glycopyrronium Seebri Breezhaler®
Formulary

 

    • 44microgram (equivalent to 55 micrograms of glycopyrronium bromide) powder capsule with device (DPI)



 


Green View adult BNF  View SPC online  View childrens BNF
Aclidinium Eklira Genuair®
Formulary

 

    • 322 microgram/dose (equivalent to aclidinium bromide 375 microgram/dose) inhalation powder (DPI)



 


Green View adult BNF  View SPC online  View childrens BNF
Ipratropium Nebules
Formulary
  • 250 microgram/1ml & 500 microgram/1ml nebuliser liquid



 

Link  MHRA Drug Safety Update (Aug 2022): Nebulised asthma rescue therapy in children: home use of nebulisers in paediatric asthma should be initiated and managed only by specialists

Green plus View adult BNF  View SPC online  View childrens BNF